Scarica l'app Stockscreener
9.68
2.33%
0.22
Dopo l'orario di chiusura:
9.18
-0.50
-5.17%
Precedente Chiudi:
$9.46
Aprire:
$9.43
Volume 24 ore:
3.91M
Relative Volume:
1.92
Capitalizzazione di mercato:
$710.68M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-2.0728
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
+0.94%
1M Prestazione:
+26.70%
6M Prestazione:
+26.54%
1 anno Prestazione:
-65.18%
Intervallo 1D:
$9.3306
$10.30
Intervallo di 1 settimana:
$8.78
$10.30
Portata 52W:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.68 | 690.86M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Discipline and Rules-Based Execution in ARVN Response - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Downgraded by The Goldman Sachs Group to "Sell" - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap DownWhat's Next? - MarketBeat
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Goldman Sachs Downgrades Arvinas (ARVN) to 'Sell', Lowers Price Target | ARVN Stock News - GuruFocus
How to forecast Arvinas Inc. trends using time seriesJuly 2025 WrapUp & Fast Gain Swing Alerts - newser.com
Goldman Sachs Downgrades Arvinas to Sell From Neutral, Cuts Price Target to $6 From $8 - MarketScreener
Can Arvinas Inc. stock beat analyst upgradesWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
Goldman Sachs downgrades Arvinas stock to Sell on competitive risks By Investing.com - Investing.com Nigeria
Is Arvinas Inc. trending in predictive chart models2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Can Arvinas Inc. stock withstand economic slowdownQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
What data driven models say about Arvinas Inc.’s futureGap Down & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-10-13 09:51:45 - newser.com
Chart overlay techniques for tracking Arvinas Inc.July 2025 Trade Ideas & Capital Efficient Trading Techniques - newser.com
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress - The Manila Times
Arvinas, Inc. to Present New Patient-Reported Outcomes Data for Vepdegestrant at ESMO Congress 2025 - Quiver Quantitative
Arvinas to Present Data from the Vepdegestrant Clinical - GlobeNewswire
Phase 3 PRO data lead: Arvinas' vepdegestrant to be presented at ESMO Oct 19–20, 2025 in Berlin - Stock Titan
What MACD signals say about Arvinas Inc.Earnings Miss & High Conviction Buy Zone Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Full technical analysis of Arvinas Inc. stockTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook By Investing.com - Investing.com South Africa
Arvinas’s SWOT analysis: vepdeg promise, pipeline shifts shape stock outlook - Investing.com
Arvinas Holding Company (ARVN) Receives a Hold from Bank of America Securities - The Globe and Mail
Piper Sandler raises Arvinas stock price target to $16 on LRRK2 degrader data - Investing.com
Arvinas Announces Positive Phase 1 Trial Results - TipRanks
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell - MarketScreener
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Top Companies in Targeted Protein Degradation MarketBristol - openPR.com
Is Arvinas Inc. reversing from oversold territoryShort Setup & Weekly Chart Analysis and Guides - newser.com
Full Stock Market News from 2025-10-05 - Stock Titan
Arvinas (ARVN) Highlights Promising Phase 1 Trial Results for AR - GuruFocus
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials By Investing.com - Investing.com Nigeria
Arvinas reports positive data for LRRK2 degrader in Parkinson’s trials - Investing.com India
Arvinas, Inc. Reports Positive Phase 1 Trial Results for ARV-102 in Healthy Volunteers and Parkinson's Disease Patients - Quiver Quantitative
Arvinas Presents Late Breaking, Positive Phase 1 Clinical - GlobeNewswire
97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation - Stock Titan
Will a bounce in Arvinas Inc. offer an exitJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
Real time alert setup for Arvinas Inc. performanceJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Arvinas Inc. stock poised for growthQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Tools to monitor Arvinas Inc. recovery probabilityWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can Arvinas' Brain-Penetrant PROTAC Deliver On Its Promise In Parkinson's Trials? - RTTNews
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):